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Abstract 
 
Pressures to expand, advancing 
technologies, and increased public 
exposure of in vitro fertilization (IVF) 
compels ongoing evaluation of the 
medical, ethical, and legal proprietary of 
this high tech infertility treatment, 
especially when used to build non-
traditional families.  Recently, the 
University of Iowa’s Center for 
Advanced Reproductive Care 
considered the possibility of adding 
gestational carrier (popularly known as 
“surrogacy”) services to our program.  
The IVF Ethics Committee considered 
practical realities and inherent ethical 
issues including the number of invested 
parties, significant economic costs, risks 
taken on by the gestational carrier, and 
the potential for free market exploitation. 
The Committee resolved that efforts to 
combat these concerns should include a 
push for industry self-regulation with 
restrictions on reimbursement, better 
professional guidance on this topic from 
professional organizations, collaborative 
research on program development, 
trends, and outcomes, and uniform laws 
to protect all parties involved.  With this 
in mind, the Committee and program 
physicians approved moving forward 
with careful institution of this program in 
collaboration with handpicked surrogacy 
agencies.   
 
1. Department of Obstetrics and Gynecology, 
Division of Reproductive Endocrinology and 
Infertility, University of Iowa Health Care, Iowa 
City, IA 52242  
 
2007 marked the 20th anniversary 
of the first in vitro fertilization (IVF) cycle 
performed at the University of Iowa’s 
Center for Advanced Reproductive Care 
(CARC).  The program has grown 
remarkably during that time, expanding 
from 30 cycles of IVF in 1987 to 473 
cycles resulting in 199 live births in 
2007.1  2009 also marked our 5,000th 
oocyte (egg) retrieval.  This growth is 
consistent with the increase in United 
States IVF treatments as a whole.  
Between 1996 and 2006, the number of 
IVF cycles has more than doubled in 
this country, growing from 64,681 per 
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year to 138,198 per year.2  The number 
of IVF live birth deliveries has increased 
more than two and a half times during 
this same period, from 14,507 per year 
to 41,343 per year.2  It is estimated that 
1% of children now born in the United 
States were conceived through IVF.2 
 
This expansion is due to a 
number of factors, including increased 
availability and exposure of IVF, 
scientific and technological 
improvements that make IVF a viable 
option for more patients, increased 
acceptance of non-traditional family 
building, and a trend in delaying 
childbearing (which increases the 
number of infertile women).  Besides a 
general increase in demand for IVF 
treatment at the University of Iowa over 
the years, the program has expanded to 
include an embryo donation program in 
1997 (for embryos already created 
through IVF and subsequently 
cryopreserved), treatment of lesbian 
couples in 2004, and treatment of single 
women in 2007.   
 
With pressures to expand, 
advancing technologies, and increased 
public exposure comes a need for 
ongoing evaluation of the medical, 
ethical, and legal proprietary of IVF 
treatments offered.  This is particularly 
true when the traditional definition of 
“family” is challenged by the 
composition of our patient populations.   
 
For this reason, each of the 
above mentioned changes at the CARC 
was preceded by consultation with the 
hospital’s legal advisory team, an 
invitation for comments and concerns 
from local care providers, and 
consideration by an IVF ethics 
committee.   
In 1999, members of the IVF 
ethics committee published an account 
of the establishment of CARC’s embryo 
donation program.3  This paper 
describes how faculty members 
responded to the problem of expanding 
numbers of cryopreserved embryos in 
storage by investigating worldwide 
practices, surveying patient desires 
regarding the disposition of their 
cryopreserved embryos, and charging 
an ethics committee with addressing the 
ethical and policy questions involved in 
establishing such a program.  The 
publication provides the IVF community 
with an example of how to ethically 
tackle new problems arising in this 
unregulated field. 
 
This practice of careful 
consideration prior to program 
expansion proved invaluable this past 
year as we contemplated adding 
gestational carrier services (popularly 
described as “surrogacy” services) to 
our CARC treatment options.  This 
service represented the only non-
experimental IVF treatment we did not 
offer; in contrast, 81% of 426 IVF 
centers reporting 2006 data to the CDC 
do offer gestational carrier treatments.2   
 
Without these services, women 
or couples with a significant uterine 
infertility factor and gay men are 
excluded from infertility treatment and 
the option of having genetically related 
offspring.  
 
Despite the availability of this 
treatment option in the United States, 
there is a relative dearth of practical 
guidance available in the literature or 
through the country’s professional 
organizations on how to appropriately 
establish a gestational carrier program.  
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The American Society for Reproductive 
Medicine (ASRM), the country’s primary 
professional organization for 
reproductive specialists, has nothing in 
their Ethics Committee Reports, 
Technical or Educational Bulletins, 
Position Statements, or Guidelines 
specifically addressing this topic.  The 
issue is only mentioned briefly in a 
report entitled “Family members as 
gamete donors and surrogates.”4  In this 
report, the ASRM comments that use of 
family members as surrogates may be 
ethically acceptable if careful counseling 
is provided and intergenerational 
surrogacy is closely scrutinized.   
 
The American College of 
Obstetricians and Gynecologists 
(ACOG) issued its first Committee 
Opinion on “surrogate motherhood” in 
1983 and most recently updated the 
statement in February, 2008.5  They 
acknowledge that this practice 
“continues to be controversial” and that 
“considerable disagreement persists 
within the medical profession, the 
medical ethics community, state 
legislatures, the courts, and the general 
public.”  The statement allows that “a 
physician may justifiably decline to 
participate in initiating surrogacy 
arrangements for personal, ethical, or 
medical reasons,” but does list expected 
responsibilities for those obstetricians 
and gynecologists who choose to assist 
with these treatments. 
 
ACOG suggests that surrogacy 
arrangements are best “overseen” by 
private nonprofit organizations, though 
they acknowledge that most surrogacy 
organizations are entrepreneurial in 
nature and thus must be closely 
investigated by the responsible 
physician.  They further counsel 
infertility specialists that the intended 
parents and surrogate mother should be 
appropriately “screened” (apparently 
medically) and provided with 
independent mental health counseling 
and legal representation.  Finally, 
infertility specialists are “encouraged to 
participate in research that is intended 
to provide data on the outcomes of 
surrogacy arrangements.”5 
With these limited guiding 
principles, we set about to answer the 
challenge set by one of our IVF ethics 
committee members who wrote, “Just 
because we can do this doesn’t mean 
we should.”  In other words, we first 
wanted to determine whether we had 
the medical, legal, economic, and 
psychosocial means to establish a 
successful gestational carrier program in 
Iowa.  Secondly, though not necessarily 
separately (since a poorly administered 
program cannot be ethically viable), we 
wanted to determine whether the 
balance of medical need, community 
support, legal acceptance, libertarian 
ideals of procreative liberty, and risks of 
harm tipped in favor of  establishing this 
program.  A description of this fact-
finding mission and decision-making 
process follows.    
 
The Basics of Gestational Carrier 
(Surrogacy) Arrangements 
 
While this phenomenon of 
carrying a child that you do not intend to 
raise appears at first to be a modern 
one, there are actually two surrogacy 
arrangements documented in the book 
of Genesis in the Old Testament of the 
Christian Bible.  In chapter 16, Abraham 
and his infertile wife, Sarah, ask her 
maid, Hagar, to bear Abraham’s 
children.  And in chapter 30, Isaac and 
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his infertile wife, Rachel, ask the same 
of her maid, Bilbah.    
 
What modern science has 
wrought, however, is an increasingly 
complex and intentionally non-traditional 
definition of family.  As Liza Mundy 
comments in her investigative report 
Everything Conceivable, “science has 
given us something new: families that 
are designed, from the start, to have 
only a single parent; to have quite a few 
parents; to have two parents, only one 
of whom is biologically related to the 
child, the other of whom is biologically 
unrelated, with a third party out there 
who is biologically related but, often, 
unknown.  Families with these qualities 
have spontaneously arisen in the past, 
and still do, of course [by war, adultery, 
epidemics, childbed fever, remarriage, 
slavery, stepparents, social upheaval, 
and shifts in gender roles], but now they 
are being consciously formed.”6 
 
“Gestational carriers,” also known 
as “surrogates,” or “contracted 
mothers”7 are women who become 
pregnant, carry, and deliver a child 
under an agreement that the child will 
be raised by another woman or couple 
(known as the “intended,” “social,” 
“rearing,” or “commissioning” 
parent(s)).6-8  These surrogates may 
have no genetic relationship to the child 
they carry (sometimes referred to as “full 
surrogates” or “gestational carriers”) or 
they can provide oocytes and therefore 
half of the child’s genetic material 
(sometimes referred to as “partial” or 
“traditional” surrogates).  For the 
remainder of this article, I will use the 
term “gestational carrier” (GC) when 
there is no genetic relationship between 
the fetus and gestating woman, 
“surrogate” when there is a genetic 
relationship, and “intended parent(s)” 
(IPs) for the person(s) who plan to raise 
the child.  
 
Any reproduction involving three 
or more parties is termed “collaborative 
reproduction.”  To complicate this 
“collaboration” further, there may be 
more than three parties involved in 
“parenting” a desired child.  The IP(s) 
may provide all or none of the gametes 
that make up the embryo.  In an 
extreme case, the IP(s) may choose a 
male donor to provide sperm, a female 
donor to provide eggs, and a GC to 
carry and deliver the child.  This type of 
reproductive “collaboration” thus 
includes five potential “parents.”   
 
There are important practical, 
ethical, legal, and policy implications of 
the differences between a surrogacy 
arrangement and a GC arrangement.  
Practically, surrogacy arrangements 
require only the placement of sperm in 
the vagina, cervix, or uterus of the 
surrogate, either by intercourse or 
artificial insemination.  Gestational 
carrier arrangements require the 
medical ovarian stimulation of the 
female IP (or oocyte donor) with weeks 
of injectable medications and 
monitoring, surgical retrieval of oocytes, 
in vitro fertilization, and transfer of 
embryos into the uterus of the 
gestational carrier.  The latter is more 
medically invasive and risky, requiring 
special medical expertise and facilities, 
and much more expensive. 
 
Artificial insemination of 
traditional surrogates can be done at 
home, avoiding clinic costs and FDA 
(Food and Drug Administration)-
mandated lab testing costs.  If done in a 
clinic setting, costs of insemination and 
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lab testing may be less than ~$1,500.  
The IVF treatment that is required in GC 
arrangements, on the other hand, 
averages $9,000 – $20,000 per 
treatment cycle, depending on whether 
an oocyte donor is used and whether 
preimplantation genetic testing is 
performed.  This may effectively “price 
out” many infertile person(s) from GC 
cycles. 
 
The Ethics and Practicalities of 
Surrogacy Law 
 
While surrogacy arrangements 
are more simple and affordable than GC 
arrangements, there are serious legal 
concerns that make using a surrogate 
more fraught than using a GC.  Because 
a surrogate is the genetic mother of the 
child in question, if she changes her 
mind it is very likely that the court can 
deem a surrogacy contract 
unenforceable and award custody of the 
child to the surrogate.  The courts tend 
to appeal to the standard of the best 
interest of the child in these cases.  
 
As lawyer and bioethicist John 
Robertson points out, “the question of 
enforcing preconception surrogacy 
agreements for rearing is the most 
controversial issue in collaborative 
reproduction.”9  Highly publicized cases 
of surrogates refusing to fulfill their 
agreed upon obligations have not 
helped to sway the courts towards 
enforcement.9  This was true in the Baby 
M case in New Jersey in 1988 (In The 
Matter of Baby M 109 NJ 396 (1988)) 
where the New Jersey Supreme Court 
deemed the pre-birth agreement 
unenforceable, named the surrogate as 
the child’s “natural mother,” and 
awarded custody of the child to the 
surrogate despite the fact that the child 
had lived with her IPs for two years.   
 
Because of such risks, most 
collaborative reproductive arrangements 
now preclude such traditional surrogacy, 
and most clinics and agencies do not 
provide these services.  Early on in the 
process of considering adding surrogacy 
treatments to our program - prior to any 
discussion by the IVF ethics committee - 
a decision was made to avoid such legal 
custody and contract battles, along with 
the potential for the greater difficulty a 
surrogate might have in relinquishing 
parentage, by restricting ourselves to 
considering GC treatment cycles only.  
Nevertheless, even these arrangements 
are legally muddy, with no unified body 
of law to which to appeal. 
 
As attorney Mark Johnson writes 
in his publication Checklist on the Law 
of Surrogacy, “traditional ‘laws on the 
books’ concerning paternity, maternity (if 
these laws address that issue at 
all),…issuance of birth certificates, 
parental rights and obligations, informed 
consent for medical procedures, ‘Roe v. 
Wade’ questions, medical insurance, 
infectious disease, pre- and post-natal 
support obligations, to name but a few, 
are wholly inadequate.”10  Gestational 
carrier arrangements have not been the 
topic of any generally adopted “uniform 
acts,” although the organization known 
as the “Uniform Law Commissioners” 
has drafted just such a “Uniform Status 
of Children of Assisted Conception 
Act”11 in an attempt to remedy this 
situation.  In the absence of general 
acceptance of any such a uniform state 
law, however, laws have been 
determined on a state by state basis 
and vary markedly.   
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New York, for example, deems 
surrogacy contracts void and 
unenforceable,12 while Texas courts will 
specifically approve and enforce 
gestational carrier arrangements to 
protect all parties involved.13  Iowa, on 
the other hand, is like most states: there 
are no laws providing guidelines or 
procedures for surrogacy 
arrangements.14  In such states, it is 
unclear what might happen if a GC 
breaches her contract or whether a new 
law severely restricting these practices 
might be enacted at any given time.  
Iowa Code 70.11, which states that it is 
unlawful to sell or purchase another 
person, does contain a specific 
exception for surrogacy arrangements.  
Otherwise, adoption procedures are 
generally utilized to transfer parental 
rights to IPs in Iowa and legislatively 
similar states.  
 
Iowa has drafted a Senate Study 
Bill (#253) entitled, “The Human 
Reproductive Technologies and 
Surrogacy Act”15 to remedy this 
situation.  In this Bill, maternity and 
paternity are granted to the surrogate / 
GC and her husband (if she is married) 
unless they “relinquish all rights and 
duties as parents of a child to be 
conceived through assisted conception.”  
A written agreement to this effect must 
be approved by the court prior to 
conception, and the intended parents 
must be a married, heterosexual couple.  
This Study Bill was first introduced in 
1996, but has yet to make it into law.  
Nationally, the American Bar 
Association produced a Model Act of 
Assisted Reproductive Technologies 
(ART) that provides an analysis of 
issues such as informed consent, 
counseling and consultation, privacy, 
the status of children of ART, payments 
to donors, heath insurance and 
professional liability.16  Again, however, 
this has not had a great deal of 
influence over state legislatures to this 
point. 
 
Nevertheless, there are many 
lawyers in the United States that 
practice “reproductive law” and have a 
good understanding of the relevant 
statutes paramount to the success of 
gestational carrier arrangements.  
These lawyers are absolutely essential 
to successful negotiation and drafting of 
contracts for the parties involved, and 
for adjudication of maternity and 
paternity.  As ACOG counsels, it is 
imperative that the GC and IP(s) are 
each assisted independently by 
separate knowledgeable 
representatives. 
 
Points addressed in a contract 
between a GC (and her family) and IP(s) 
are best explored in conjunction with 
psychological as well as legal counsel.  
Even if not mandated by state law, 
contracts are essential and should 
include all expectations of all parties 
during the evaluation (including 
background checks and psychological 
testing, for example), medical 
stimulation (including amount of time the 
GC needs to be available), pregnancy 
(including what prenatal testing might be 
performed, what will happen if 
complications develop, and whether the 
GC would undergo an abortion for fetal 
abnormalities), delivery (including 
whether C-section is mandated for 
certain circumstances), and post-partum 
(including how communication will 
continue between parties and how birth 
certificates will be prepared).   
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In our exploration of the legal 
aspects of GC arrangements in Iowa, 
we discovered that practicing 
reproductive law specialists were not 
readily available in our local community.  
Furthermore, many of these sub-
specialists are found practicing in 
conjunction with, or as owners of, 
surrogacy agencies.  It became clear 
that the most appropriate way to find 
well-trained legal representation for our 
patients was to turn to these agencies 
for assistance.  Since there are no 
gestational carrier / surrogacy agencies 
in the state of Iowa, so we turned our 
attention to neighboring Midwestern 
states. 
 
The Realities and Ethics of the 
Business World of Surrogacy  
 
Most IVF programs that offer 
oocyte (egg) donor treatments or 
gestational carrier treatments use 
private, for-profit agencies to advertise 
for donors / carriers, screen and match 
potential candidates, and broker 
financial and other arrangements 
between the parties.  While the 
University of Iowa CARC has been 
offering oocyte donor treatment for 
many years, we have been in the 
minority of programs that provide all of 
these services in-house.  This has 
allowed us to maintain control over all 
aspects of the program, guaranty high 
quality, and keep costs low for our 
patients.  
 
Because of our lack of 
experience with egg donor agencies, 
however, we were unprepared for the 
infertility business world that became 
apparent in investigating surrogacy 
agencies.  This for-profit world has 
resulted from the U.S. free market 
growing to meet the needs of the 
infertile population.  It is difficult to know 
exactly how many egg donor or 
gestational carrier agencies exist at any 
given time in the United States, since 
there is no certification process or 
regulatory agency governing these 
businesses.  ASRM does have a list of 
87 egg donor agencies that have 
“signed an agreement with the Society 
for Assisted Reproductive Technology 
that states that they will abide by the 
ASRM Ethics Committee Guidelines 
governing the payment of egg donors.”  
 
Fifty of the 87 agencies also 
provide facilitation of GC cycles.  The 
vast majority of these agencies are for-
profit, and most of these appear to be 
owned by entrepreneurial women, with 
or without training in healthcare, who 
have experienced infertility or acted as a 
GC personally in the past.  A smaller 
number of agencies have been started 
by, or in conjunction with, reproductive 
lawyers with experience negotiating 
gestational carrier contracts and 
parentage.  Several describe their 
agencies as “boutique,” and a few have 
specifically developed to assist sub-
populations such as Asian immigrants, 
Orthodox Jews, or international IP(s).   
 
It is not a surprise that costs to 
IPs and reimbursement of GCs vary 
widely, given the entrepreneurial nature 
of the business, the lack of regulation, 
the variety of locations and clients, and 
the uncertainty surrounding the 
appropriate level of compensation for 
gestational carriers.  GCs who do not 
ask for compensation (beyond payment 
for medical bills and insurance, short-
term life insurance, legal fees, and 
expenses) are known as 
“compassionate” or “altruistic” carriers, 
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and are often family members or friends 
of the IPs.  “Compensated” GCs, by far 
the most common in the United States, 
also receive payments that are 
distributed throughout the pregnancy.  
The total amount of this “compensation” 
seems to vary from ~$18,000 - $30,000, 
and is higher if the carrier has 
successfully provided the service in the 
past.  Reimbursement may also be 
higher if the carrier is pregnant with 
multiples, if she has a C-section, if she 
requires an invasive prenatal procedure, 
or if she has lost wages due to her 
fulfillment of the gestational carrier role. 
 
A broad estimate of the costs of 
parenting with a gestational carrier and 
agency totals between $50,000 and 
$150,000, including payments to the 
GC, an egg donor (if necessary), 
brokering agencies, an IVF clinic, and 
lawyers, plus medical and life insurance 
for the GC, escrow fees, and travel 
expenses.  Amazingly, approximately 
1.4% of the 138,198 IVF cycles 
performed in 2006 included a GC, 
despite these exorbitant costs. 
 
Reimbursement / compensation 
of GCs is one of the thorniest legal and 
ethical issues both in the United States 
and worldwide.  It is this issue more 
than any other that has prompted both 
popular and legal rejection of contracted 
relationships between IPs and GCs, and 
lawyers must be careful to explore 
whether statutes against human 
“trafficking” may be applied when money 
changes hands in GC arrangements in a 
given state.   
 
In Canada, the Assisted 
Reproduction Act of 2004 makes it a 
“criminal offense to pay or offer to pay a 
woman to act as a surrogate; to pay or 
offer to pay a person to arrange for the 
services of a surrogate; to advertise 
payment for surrogacy or the 
arrangement of surrogacy.”17 Even 
reimbursing a surrogate for her 
expenditures during gestation is now a 
controlled act in Canada.  Australia and 
the United Kingdom similarly permit 
altruistic, but not commercial, 
surrogacy.17        
 
Certainly, monetary 
compensation raises ethical issues 
regarding protection of the GC’s 
interests, body, and privacy, as well as 
protection of the intrinsic value of human 
life.  Opponents of GC / surrogate use 
have described this practice as 
anywhere from “unsavory” to “immoral,” 
since they believe that the gestating 
women are treated as means to an end 
rather than ends in themselves. 7  There 
are concerns that a woman will be 
considered no more than a “womb for 
rent” and that her privacy and right to 
autonomous decision-making will be 
discounted.  Furthermore, monetary 
conpensation may induce a woman to 
discount her physical or psychological 
risks or to conceal important medical 
information.7,18,19  Compensation also 
creates the potential for exploitation.  In 
general, oocyte donors are selected 
based on beauty, intelligence, health, 
and youth, and gestational carriers are 
selected based on past reproductive 
performance, compliance, and 
willingness to dedicate a great deal of 
time and effort to their role.6 The latter 
woman is very often of lower 
socioeconomic status than an egg donor 
or the IPs and is susceptible to 
economic exploitation.6  
 
Increasingly common is a type of 
“reproductive tourism” in which relatively 
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wealthy infertile couples send their 
embryos to be gestated by foreign 
women for a fraction of the cost of this 
practice in the United States.20, 21  India 
is currently the favored location for this 
practice, where surrogacy is legal and 
clinics have arisen specifically to cater 
to these “tourists.”  Reports from India 
are surfacing that suggest gestational 
carriers are inadequately informed of the 
process and risks, and that many are 
illiterate.20,21  All of this adds to the aura 
of injustice surrounding the business of 
gestational carrier arrangements. 
 
Remuneration related to 
transferring embryos and newborn 
children may also imply that they are 
commodities to be bought and sold, and 
this is counter the value of, and intrinsic 
respect for, human life.18 Some compare 
this situation to adoption (where it is 
unacceptable to pay women to “adopt 
out” their children) or to organ donation 
(where there is a prohibition against 
paying someone to donate organs or 
tissue), and wonder how it can be 
ethically acceptable to pay gestational 
carriers.   
 
On the other hand, it is ethically 
acceptable to pay research subjects for 
their time, inconvenience, and 
discomfort.  There is no question that 
IVF treatments and a 40-week 
pregnancy, with its attendant physical, 
emotional, and psychological risks and 
challenges, represents an sacrifice of 
time, convenience, and comfort for the 
GC.  It is also fair to compare the 
challenges of the gestational carrier’s 
experience to other positions of 
employment, where time, effort, risk-
taking, care, and talent are 
remunerated.  The common practices of 
distributing payments to GCs over the 
course of the pregnancy, instead of in 
one lump sum after the child is 
delivered, and of compensating 
experienced GCs more than first-time 
GCs, are consistent with this 
conceptualization. 
 
Nevertheless, these ethical 
concerns related to compensation 
become more and more appropriate as 
GC payment amounts increase.  For this 
reason, the unregulated nature of the 
free market system in the United States 
should be tempered by practical 
guidelines or oversight from biomedical 
ethics experts and professional 
organizations.  While these do not exist 
currently, similar guidelines were 
developed by the ASRM Ethics 
Committee for financial compensation of 
oocyte donors.  In this report, the 
Committee concludes that, 
“compensation should be structured to 
acknowledge the time, inconvenience, 
and discomfort” of the medical 
treatments, and that, “compensation 
should not vary according to the 
planned use of the oocytes, the number 
or quality of oocytes retrieved, the 
number or outcome of prior donation 
cycles, or the donor’s ethnic or other 
personal characteristics.”18   
 
The fact that for-profit agencies 
facilitate many of these treatments in the 
United States is also counter to the 
research mandate that good medical 
practice demands, and many 
commentators feel that IVF treatments 
using surrogates and GCs has 
proceeded without adequate preliminary 
experimental scientific study.5,22  
Agencies that are competing for GCs 
and IPs are not likely to feel much 
scientific responsibility or to ask their 
clients to take part in studies, however.  
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As Reproductive Endocrinologist Dr. 
Howard Jones writes, “…let’s face it – 
entrepreneurial business has a different 
ethic and goal than science.”22   
 
It is nevertheless true that 
agencies are in a unique position to 
provide the best quality care for infertility 
patients who need GCs to build a family.  
The very fact of their existence suggests 
that clinical IVF programs have not 
generally have the staff, experience, or 
connections necessary to efficiently 
screen and match GCs, coordinate 
logistics, arrange medical treatments, 
facilitate legal representation, and 
support very complex and fragile human 
relationships during a pregnancy.  
Agencies established by prior intended 
parents or gestational carriers have 
blossomed because these individuals 
saw a void that could be filled. 
 
Our IVF Ethics Committee 
carefully considered developing a 
gestational carrier program completely 
in-house vs. working with established 
agencies.  In the end, the decision was 
made to provide the medical 
assessments and treatments ourselves 
while working with a short list of well-
respected agencies that already have 
the staff and experience to facilitate 
coordination of recruiting, matching, 
payment, and legal contracts.  One of 
the most compelling reasons behind this 
decision was concern about the 
daunting task of supporting all the 
involved parties throughout a long 
treatment and pregnancy process.  This 
would require time, skills and personnel 
that we did not have in place.  Secondly, 
we were uncertain of the level of need 
for these services in our community and 
it seemed imprudent to develop a 
complicated new program of services if 
they would be used only rarely.  Finally, 
prevailing legal opinion suggested that it 
would be wise to transfer the legal 
responsibilities of contract negotiation 
and parentage agreements away from 
the purview of the hospital in order to 
protect the institution from litigation. 
 
Nevertheless, this decision meant 
giving up the quality control and cost 
containment that we have with our 
oocyte donation program.  For this 
reason, the ethics committee felt it vital 
to closely investigate the agencies with 
which we would collaborate.  This was 
done through Internet research, phone 
conversations, and visits from agency 
representatives for presentations and 
face-to-face meetings.  Most 
importantly, the Committee felt that our 
CARC’s medical inclusion and exclusion 
criteria for IPs and GCs must be 
consistent with, or be allowed to trump, 
the criteria laid out by the collaborating 
agencies (see Box 1). 
 
The Clinical and Medical Ethics 
Issues in IVF Gestational Carrier 
Treatment 
 
Some on the ethics committee 
argued as a matter of gender equity and 
libertarian ethics that any woman should 
be able to decide against gestating and 
delivering her child and contract with a 
competent and informed gestational 
carrier, regardless of this intended 
mother’s physical or medical ability to 
carry the child herself.  The prevailing 
committee opinion, however, was in line 
with the ACOG Committee Opinion 
which states that, “because of the risks 
inherent in surrogacy arrangements, 
such arrangements should be 
considered only in the case of infertility 
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or serious health-related needs, not for 
convenience alone.”5    
  
 There are a number of medical 
reasons why someone may be unable to 
carry and/or deliver a child, or may be 
counseled against this.  Congenital 
abnormalities or scarring may leave a 
woman’s uterus unable to carry a 
pregnancy to term.  Recurrent 
pregnancy losses without an apparent 
genetic link, especially those occurring 
in the second trimester, may also be an 
indication for using a gestational carrier.  
Pregnancy is impossible for women who 
have undergone hysterectomy at a 
young age for such issues as 
uncontrollable bleeding or endometrial 
or cervical cancer, and pregnancy is 
medically contraindicated in women with 
serious heart or lung abnormalities, with 
spinal cord injuries, or with significant 
bleeding or clotting disorders.  A 
widower with cryopreserved embryos 
genetically related to his deceased 
partner may wish to gestate these 
embryos and raise the offspring.  
Finally, gay men require a gestational 
carrier or surrogate to build their 
genetically related families. 
 
The CDC reports that 1,042 fresh 
non-oocyte donor IVF cycles in 2006 
involved gestational carriers 
(approximately 1.4% of all such cycles).  
An unknown additional number of 
oocyte donor IVF cycles involved GCs, 
including those with gay male intended 
parents (a growing minority of IPs).  
Interestingly, the success rates of GC 
cycles in all age groups were better than 
those in which the intended mother 
carried the pregnancy.  That is not to 
say, however, that relatively high 
pregnancy rates represent a medical 
reason to use GCs for more IVF cycles. 
Though the CARC had been 
approached by several prospective IPs, 
and had assisted with clinical monitoring 
of local GCs being treated by other 
clinical programs, we were unaware of a 
significant demand in our local 
population for GC services when we 
began our investigation.  Simply 
speaking to local obstetrics and 
gynecology providers about our plans to 
consider starting a GC program brought 
a flurry of interest from potential IPs, 
however.  Current or past IVF patients 
who might benefit from GC treatment 
(such as those with recurrent failed IVF 
cycles or those who had remaining 
cryopreserved embryos from cycles 
prior to hysterectomy) learned of the 
program and got on a waiting list.  
These developments, in the absence of 
any focused advertising of the program, 
convinced us that there is a desire for 
these services in our community. 
  
 Because it is difficult to anticipate 
all possible medical indications for GC 
use, the ethics committee agreed that 
acceptance into the program must be 
done on a case by case basis with the 
consensus of all physicians in the 
program.  Clinical inclusion and 
exclusion criteria developed by the IVF 
team and ethics committee are listed in 
Box 1. Developing this list prompted 
further ethics committee discussion 
regarding the social vs. medical value of 
setting age limits for parenting.  While 
this question was not definitively 
answered, a consensus was reached 
that we would be consistent with our 
existing guidelines for donor oocyte and 
cryopreserved embryo recipients, for 
whom treatment ceases at their 50th 
birthday.  Possible exceptions could be 
brought to the clinical team on a case by 
case basis. 
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In our discussion of how non-
traditional families fit into the criterion of 
medical necessity, there was relatively 
limited debate over whether single men 
or gay male couples could be described 
as having a medical vs. social need for 
a gestational carrier.  In the end, there 
was general agreement that these IPs 
would be accepted into the program.  
Perhaps the willingness to offer GC 
services to the single and gay male 
population can be attributed to the 
general acceptance of current 
treatments of single and lesbian women 
and couples or to a general sociocultural 
acceptance of male parenting.  The 
committee also discussed the fact that 
there is no current evidence that marital 
status or sexual orientation affects one’s 
ability to parent or one’s interest in 
childbearing and rearing.     
 
Lawyer and bioethicist John 
Robertson articulates the primacy of 
procreative liberty in Children of Choice: 
“procreative liberty [the freedom to 
decide whether or not to have offspring] 
is a deeply held moral and legal value 
that deserves a strong measure of 
respect in all reproductive activities,” 
and this value “should be equally 
honored when reproduction requires 
technological assistance,”9 Indeed, 
medical procedures such as IVF open 
up choices to many infertile people 
otherwise unable to fulfill their 
fundamental desire to have a genetic 
family, and gestational carrier 
arrangements allow us to avoid further 
discrimination against single men or gay 
male couples.  Our ethics committee’s 
decision was also in line with the ASRM 
Ethics Committee recommendation that 
“programs should treat all requests for 
assisted reproduction equally without 
regard to marital status or sexual 
orientation.”23 
 
Risks of Harm to Gestational Carriers 
and Offspring 
 
As bioethicist Barbara Berg 
notes, “the acceptance of medical 
interventions to maximize the choices 
available to infertile women [and men] is 
not the same as uncritically accepting 
the medicalization of reproduction.”9  
Despite the fact that GCs are used 
ultimately for the same ends as 
standard IVF – to help an infertile 
person or couple produce offspring to 
rear – we must acknowledge that 
inserting a very invested third party into 
the process results in unique, and often 
very controversial, issues and risks.   
 
Medically and ethically, the GC 
must be treated as an independent 
patient in this process.  This important 
fact is at risk of being overlooked by the 
surrogacy agency, whose fees are 
coming from IP(s), and by the IVF 
clinics, which are first approached for 
treatment by the IP(s).  It is vital that the 
GC has her own legal representative (as 
mentioned above) to ensure her 
interests are represented in the contract 
negotiations, that she is fully informed, 
consented, and treated objectively by 
the IVF clinic, that she has an 
independent obstetrician who 
acknowledges her autonomy to make 
medical decisions during the pregnancy, 
and that she has optimal psychological 
support throughout the process. 
 
One of the most important 
elements that must be in place to 
optimally prepare a GC for her 
upcoming experience, and to support 
her throughout the process, is an 
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experienced health psychologist.  GCs 
must meet with the psychologist both 
independently from their IP(s) and then 
together with them.  An experienced and 
talented psychologist can pick up on 
risky issues and can give the GC a way 
to opt out of the process.  He or she can 
help make the optimal match between 
the involved parties based on 
characteristics and expectations.  
 
While these efforts may represent 
the best possible way to maintain 
respect for a GC’s rights, Barbara Berg 
echoes a common concern that “the 
notion that a woman can predict her 
level of attachment to her fetus and 
should be held to a previously signed 
contract is unacceptable.”19  Indeed, 
pregnancy is a profoundly life-changing 
event that may also risk the health and 
life of the gestating woman (there were 
569 maternal deaths in the United 
States in 2006).  It is difficult to imagine 
how one can fully inform a potential GC 
of the complexity of her upcoming 
experience. 
 
On the other hand, some have 
argued that “surrogacy is, at least 
potentially, an example of what feminist 
bioethicist Barbara Katz Rotheman calls 
‘reproductive communism,’ in which 
women help each other through all 
stages of childrearing depending on 
their desires and abilities.”6  While it may 
be difficult to fully inform a potential GC 
what she is about to undertake, 
assuming that she cannot make a 
rational decision about her reproductive 
intentions may be equally unacceptable.  
As John Robertson points out, “rejection 
of preconception intentions to fix 
postbirth rearing rights and duties 
seems to be based on paternalistic 
attitudes toward women or on a 
symbolic view of maternal gestation.”9   
 
In an effort to maintain 
consistency and quality control of our 
GC program, the ethics committee 
initially proposed that all GCs and IPs 
be screened by our program’s health 
psychologist.  We came to discover, 
however, that our chosen agencies have 
health psychologists with markedly more 
experience in this arena and with 
connections to the Mental Health 
Professionals Group of the ASRM.  
Furthermore, it became clear that it is 
much more practical to use health 
psychologists located near the agency 
offices so that these specialists can 
facilitate meetings between the GCs and 
IPs and can offer support during the 
pregnancy by way of communication 
with the agency representatives.   
 
Perhaps the most concerning 
issue in this debate is that of potential 
harms to the offspring or other existing 
children affected by these treatments.  
There are no good data regarding risks 
and benefits to the children resulting 
from GC or surrogacy arrangements5,8, 
and yet they are the only persons who 
have not elected to be involved.  
Certainly, years of legal battles over 
custody can be assumed to be harmful 
and thus effective psychological 
screening of all parties and good legal 
representation are vital to avoiding this 
situation.  Others suggest that “proper 
experimental design and proper data 
collection, followed by rigorous analysis 
and peer review”22 of family outcomes 
should be undertaken before these 
services are expanded any further.  It is 
interesting to weigh any potential harm 
to the offspring against the alternative of 
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non-existence if the reproductive 
assistance had not been provided at all. 
 
Conclusion 
 
The issues surrounding 
gestational carrier arrangements in 
assisted reproductive care are truly 
unique: the number of invested parties, 
the significant economic costs, the 
extraordinary risks taken on by the GC, 
and the multiple contentious ethical 
dilemmas, such as concerns regarding 
the free market response to the growing 
infertile population.  Adequately 
balancing the rights of all involved 
parties with an individual patient’s 
procreative liberty right requires careful 
planning and application of policies.  
While it is possible to do this 
successfully, it is not surprising that 
some IVF programs have found they 
cannot adequately meet these 
challenges and thus cannot offer 
appropriate GC services to their 
patients.  The number of these 
programs is decreasing, however.  
 
When presented with this 
challenge in our IVF program, we 
approached our IVF ethics committee 
with some background information and 
asked them to consider the question of 
whether we could, and should, expand 
our treatment options to include GC 
treatments.  Interestingly, we found that 
the question of practicalities (the 
“could”) was more contentious and 
difficult to resolve than the question of 
ethical propriety (the “should”).  Perhaps 
the reason for this lies in the current 
sociocultural and ethical climate in 
which privacy and libertarianism are 
valued, allowing wide latitude in the 
achievement of the goal of begetting 
children.   
Into this wide latitude has jumped 
the business world of surrogacy 
agencies who take advantage of what 
we came to understand during our 
investigation – that the logistics of 
gestational carrier cycles are daunting 
and at the same time vital to 
administering an ethical program.  While 
filling this important role, for-profit 
agencies have unfortunately added to 
the aura of commercialism, especially 
as fees and GC payments continue to 
rise.  Efforts to combat these concerns 
should include a push for industry self-
regulation, with restrictions on 
reimbursement.   
 
We also came to conclude that 
IVF clinics would benefit from better 
professional guidance on this topic from 
the ASRM.  Acknowledgement of this 
growing treatment area may help foster 
important collaborative research on 
program development, trends, and 
outcomes.  And for courts and invested 
parties across the country, uniform laws 
dealing with this issue are far overdue.  
With these aforementioned details and 
future wishes in mind, our IVF ethics 
committee gave the approval to move 
forward with development and institution 
of a gestational carrier program in 
collaboration with handpicked 
Midwestern surrogacy agencies. 
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Box 1: Clinical inclusion / exclusion criteria for gestational carriers and intended 
parents participating in University of Iowa’s gestational carrier program 
 
Intended parents: 
1. must have a medical reason that the female cannot carry and/or deliver a 
pregnancy 
2. single parents must be less than 50 years old, or a couple less than 100 
years in total age (though exceptions may be made on a case by case 
basis) 
3. must be willing to cryopreserve excess embryos that are not transferred in 
a fresh cycle 
4. are allowed to limit the number of oocytes that are inseminated (though this 
should be discouraged) 
 
Gestational carriers: 
1. must be between 21 and 40 years old 
2. must have had an uncomplicated pregnancy and delivery in the past, and 
parented that child 
3. must have had no more than one C-section 
4. must be a non-smoker with no active drug or alcohol abuse issues 
5. must not provide the oocytes for the intended pregnancy (i.e. no traditional 
surrogacy) 
6. must not have a history of an intimate relationship with either intended 
parent 
7. must not be the daughter or niece of the intended parent(s) 
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